[Current status of hematopoietic stem cell transplantation in China: an analysis of results registered at China Bone Marrow Transplantation Registry in 1998].
To explore the application of stem cell transplantation (SCT) and the strategy for improving the SCT outcome. Summarizing the data registered at China Bone Marrow Transplantation Registry (CBMTR) in 1998 to estimate the probabilities of disease free survival (DFS). There were 68 SCT teams registered. Thirty of them performed both allogeneic -SCT (allo-SCT) and autologous-SCT (ASCT). Up to Aug 31, 1998, a total of 1,840 SCT cases were registered, 38.6% of them were allo-SCT, 59.0% were ASCT, and 9 cases were syngeneic SCT. The probabilities of 3 year DFS for acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) in first complete remission (CR(1)) were 70.0% and 48.2%, respectively. For chronic myeloid leukemia (CML) in first chronic phase (CP(1)), 3 year DFS was 64.2%. The probability of 3 year DFS of ASCT for the AML-CR(1) patients was similar to that of the AML > CR(1) patients, but after ASCT, the ALL > CR(1) patients had much less probability of 3 year DFS than that of the CR(1) patients. There were 5 cases of volunteer marrow transplantation (VMT) registered. Two of them are alive, two died of relapse, and one died of infection. SCT including VMT should be performed while patients were in an ideal state of remission.